Introduction
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
Information is being updated
You need to login to view information
Charter capital
Business Size and Operations
Company Size
Total Assets
| A10 (Bellow 100 B) | A9 (100 - 200 B) | A8 (200 - 400 B) | A7 (400 - 600 B) | A6 (600 - 800 B) |
| A5 (800 - 1000 B) | A4 (1000 - 1500 B) | A3 (1500 - 2000 B) | A2 (2000 - 2500 B) | A1 (Above 2500 B) |
Owner’s Equity
| E10 (Bellow 100 B) | E9 (100 - 200 B) | E8 (200 - 400 B) | E7 (400 - 600 B) | E6 (600 - 800 B) |
| E5 (800 - 1000 B) | E4 (1000 - 1500 B) | E3 (1500 - 2000 B) | E2 (2000 - 2500 B) | E1 (Above 2500 B) |
Business Activities
Revenue
| R10 (Bellow 100 B) | R9 (100 - 200 B) | R8 (200 - 400 B) | R7 (400 - 600 B) | R6 (600 - 800 B) |
| R5 (800 - 1000 B) | R4 (1000 - 1500 B) | R3 (1500 - 2000 B) | R2 (2000 - 2500 B) | R1 (Above 2500 B) |
Number of employee
| L10 (Bellow 100 Peoples) | L9 (100 - 200 Peoples) | L8 (200 - 400 Peoples) | L7 (400 - 600 Peoples) | L6 (600 - 800 Peoples) |
| L5 (800 - 1000 Peoples) | L4 (1000 - 1500 Peoples) | L3 (1500 - 2000 Peoples) | L2 (2000 - 2500 Peoples) | L1 (Above 2500 Peoples) |
Company’s Market Position
Profitability within the Industry
Return on Total Assets (ROA)
| Bottom 25% | 25%-m | m-25% | Top 25% |
Return on Equity (ROE)
Net Profit Margin (ROS)
Current Ratio
| Bottom 25% | 25%-m | m-25% | Top 25% |
Total asset turnover
| Bosttom 25% | 25%-m | m-25% | Top 25% |